Method for non-invasive measurement of an analyte

• US 6,377,828 B1
• Filed: 01/10/2000
• Issued: 04/23/2002
• Est. Priority Date: 11/12/1997
• Status: Expired due to Term

• Current Assignee: Lightouch Medical, Inc.
• Original Assignee: Lightouch Medical, Inc.
• Inventors: Chaiken, Joseph, Peterson, Charles M.
• Primary Examiner(s): WINAKUR, ERIC FRANK
• Application Number:
  US09/480,375
• Time in Patent Office: 834 Days
• Field of Search: 600/310, 600/316, 600/322, 600/476, 356/39, 356/301
• US Class Current: 600/316
• CPC Class Codes: A61B 5/14532 for measuring glucose, e.g. by tissue impedance measurement
• CPC Class Codes: A61B 5/1455 using optical sensors, e.g. spectral photometrical oximeters
• CPC Class Codes: A61B 5/14553 specially adapted for cerebral tissue
• CPC Class Codes: G01N 21/49 within a body or fluid
• CPC Class Codes: G01N 21/65 Raman scattering

Abstract

Disclosed is a method and apparatus for measuring an analyte in a tissue of a subject. The method comprises contacting the tissue with electromagnetic radiation having a first excitation wavelength, wherein the first excitation wavelength is substantially equal to an absorption wavelength of a temperature probe within the tissue. The temperature probe and the analyte are sufficiently proximate to one another that energy deposited into one by absorption of radiation is transferred to the other. The Raman spectra emitted by the tissue are collected and analyzed to determine a concentration of analyte present in the tissue. The analysis can comprise measuring the Raman spectra associated with the temperature probe. In addition, the method can include simultaneously contacting the tissue with electromagnetic radiation having the first excitation wavelength and with electromagnetic radiation having a second excitation wavelength, wherein the second excitation wavelength is substantially equal to an absorption wavelength of the analyte. The analysis comprises comparing the spectra emitted in response to the first excitation wavelength in the presence and in the absence of the second excitation wavelength. In another embodiment, the analysis comprises measuring the anti-Stokes component of the Raman spectra associated with the analyte. The method provides a non-invasive measurement of blood glucose, using hemoglobin as the temperature probe.

Claims

1. A method of measuring an analyte in a tissue of a subject comprising:

(a) contacting the tissue with electromagnetic radiation having a first excitation wavelength, wherein the first excitation wavelength is sufficiently absorbed by a temperature probe within the tissue so as to increase the temperature of the temperature probe, and wherein the temperature probe and the analyte are sufficiently proximate to one another that energy deposited into one by absorption of radiation is transferred to the other so as to enhance anti-Stokes spectra scattered by the analyte;

(b) collecting the Raman spectra emitted by the tissue, wherein the Raman spectra comprise anti-Stokes spectra associated with the analyte; and

(c) analyzing the collected spectra to determine a concentration of the analyte present in the tissue.

2. The method of claim 1, further comprising contacting the tissue with electromagnetic radiation having a second excitation wavelength in the near infrared region.

3. The method of claim 1, wherein the first excitation wavelength is in the near infrared region.

4. The method of claim 1, wherein the collecting further comprises substantially excluding Raman Stokes spectra emitted by the tissue.

5. The method of claim 1, wherein steps (a)-(c) are performed while the tissue is replete with blood and while the tissue is depleted of blood, and wherein the analyzing comprises determining the difference between the spectra collected in the blood replete and blood depleted states.

6. The method of claim 1, wherein the tissue is blood, ear lobe, muscle, skin, breast or brain.

7. The method of claim 1, further comprising the step of determining blood volume.

8. The method of claim 1, wherein the first excitation wavelength is about 647 to about 400 nm.

9. The method of claim 1, wherein the first excitation wavelength is about 550 to about 400 nm.

10. The method of claim 1, wherein the first excitation wavelength has a bandwidth of about 0.03 nm to about 0.000003 nm.

11. The method of claim 1, wherein the temperature probe is hemoglobin, carboxyhemoglobin, myoglobin, melanin or bilirubin.

12. The method of claim 1, wherein the analyte is glucose, urea, creatinine, pyruvate, tyrosine, tryptophan, bicarbonate, an electrolyte, lactic acid, a drug, O₂, CO₂ or NO.

13. The method of claim 1, wherein the subject is a vertebrate.

14. The method of claim 13, wherein the vertebrate is a mammal, bird, reptile or fish.

15. The method of claim 14, wherein the mammal is human, bovine, porcine, ovine, mutine, equine, canine, or feline.

16. The method of claim 1, wherein the electromagnetic radiation comprises light emitted by a laser.

17. A method of measuring an analyte in a tissue of a subject comprising:

(a) contacting the tissue with electronagnetic radiation having a first excitation wavelength in the near infrared region and a second excitation wavelength at an in isosbestic point for oxy-deoxyhemoglobin binary equilibrium, wherein the first excitation wavelength is sufficiently absorbed by a temperature probe within the tissue so as to increase the temperature of the temperature probe, and wherein the temperature probe and the analyte are sufficiently proximate to one another that energy deposited into one by absorption of radiation is transferred to the other so as to enhance anti-Stokes spectra scattered by the analyte;

(b) collecting the Raman spectra emitted by the tissue, wherein the Raman spectra comprise anti-Stokes spectra associated with the analyte; and

(c) analyzing the collected spectra to determine a concentration of the analyte present in the tissue;

wherein steps (a)-(c) are performed while the tissue is replete with blood and while the tissue is depleted of blood, and wherein the analyzing comprises determining the difference between the spectra collected in the blood replete and blood depleted states and determining blood volume.

18. The method of claim 17, wherein blood volume is determined by dividing intensity of isosbestic points wavelength radiation injected into the tissue by intensity of isosbestic points wavelength radiation returned from the tissue.

19. The method of claim 17, wherein the second excitation wavelength is about 805 or about 580 nm.